Background: Since 2021, high-risk Human Papilloma Virus (HR-HPV) testing has been the recommended screening test for cervical cancer for all settings;either used alone in a “test and treat” strategy, or with a triag...Background: Since 2021, high-risk Human Papilloma Virus (HR-HPV) testing has been the recommended screening test for cervical cancer for all settings;either used alone in a “test and treat” strategy, or with a triage test, with or without biopsy, before treatment. Cameroon has rolled out immunization against HPV 16 and 18, but studies show a higher prevalence of non-16/18 HR-HPV types. Objectives: Determine the prevalence of precancerous lesions, in women with HR-HPV infection and evaluate association of digital cervicography (DC) VIA/VILI positivity with HPV serotype, as a measure of their contribution to precancer and cancer incidence. Methodology: The study was cross-sectional, descriptive, and analytic. It took place at the Etoug-Ebe and Ekoudoum Baptist Hospitals in Yaoundé, during the period April-September 2022. We reviewed the records of women screened for cervical cancer between February 2020 and December 2021 and evaluated the prevalence of lesions on digital cervicography (DC) with VIA/VILI for women positive for HR-HPV serotypes. The data were analyzed using SPSS version 20.0 for Windows. P values Results: We identified 315 cases with a positive HR-HPV deoxyribonucleic acid (DNA) test, 224 (71.1%) had a DC VIA/VILI triage test done. Of these, 30 (13.4%) women had a positive DC VIA/VILI, with five women (2.2%) having lesions suggestive of cancer. Out of 11 cases positive for HPV 16 alone, 05 (45.5%) had a positive DC VIA/VILI test. Of the 14 cases positive for HPV 18 alone, 03 (21.4%) had a positive VIA/VILI, meanwhile only 19 (10.7%) of the 177 cases positive for non-16/18 HPV had a positive VIA/VILI test. Conclusion: A high proportion of women (13.4%) with HR HPV had a positive DC VIA/VILI, with a significant proportion (2.2%) having lesions suggestive of invasive cervical cancer HR-HPV serotype was associated with DC VIA/VILI positivity;HPV 16 had the strongest association (45.5%), followed by HPV 18 (21.4%), and non-16/18 HR-HPV (10.7%), suggesting a decreasing order of oncogenicity.展开更多
Hepatocellular carcinoma(HCC)is one of the most common malignant tumors.Identification of the underlying mechanism of HCC progression and exploration of new therapeutic drugs are urgently needed.Here,a compound librar...Hepatocellular carcinoma(HCC)is one of the most common malignant tumors.Identification of the underlying mechanism of HCC progression and exploration of new therapeutic drugs are urgently needed.Here,a compound library consisting of 419 FDA-approved drugs was taken to screen potential anticancer drugs.A series of functional assays showed that desloratadine,an antiallergic drug,can repress proliferation in HCC cell lines,cell-derived xenograft(CDX),patient-derived organoid(PDO)and patient-derived xenograft(PDX)models.N-myristoyl transferase 1(NMT1)was identified as a target protein of desloratadine by drug affinity responsive target stability(DARTS)and surface plasmon resonance(SPR)assays.Upregulation of NMT1 expression enhanced but NMT1 knockdown suppressed tumor growth in vitro and in vivo.Metabolic labeling and mass spectrometry analyses revealed that Visinin-like protein 3(VILIP3)was a new substrate of NMT1 in protein N-myristoylation modification,and high NMT1 or VILIP3 expression was associated with advanced stages and poor survival in HCC.Mechanistically,desloratadine binds to Asn-246 in NMT1 and inhibits its enzymatic activity,disrupting the NMT1-mediated myristoylation of the VILIP3 protein and subsequent NFκB/Bcl-2 signaling.Conclusively,this study demonstrates that desloratadine may be a novel anticancer drug and that NMT1-mediated myristoylation contributes to HCC progression and is a potential biomarker and therapeutic target in HCC.展开更多
目的评价甲泼尼龙对呼吸机相关性肺损伤(VILI)大鼠肺组织瞬时受体电位香草酸4 (TRPV4)/基质金属蛋白酶2/9(MMP-2/MMP-9)信号通路的影响。方法清洁级雄性SD大鼠100只,采用随机数字表法分为5组(n=20):对照组(C组)、机械通气组(V组)、甲泼...目的评价甲泼尼龙对呼吸机相关性肺损伤(VILI)大鼠肺组织瞬时受体电位香草酸4 (TRPV4)/基质金属蛋白酶2/9(MMP-2/MMP-9)信号通路的影响。方法清洁级雄性SD大鼠100只,采用随机数字表法分为5组(n=20):对照组(C组)、机械通气组(V组)、甲泼尼龙组(Mp组)、甲泼尼龙+GSK1016790A组(MpG组)、HC-067047组(H组)。C组不行机械通气,自主呼吸空气4 h;V组机械通气(RR 40次/min,VT 40 m L/kg,I∶E 1∶1,PEEP 0,Fi O221%) 4 h;Mp组在机械通气前20 min静脉输注甲泼尼龙10.0 mg/kg;MpG组在给予甲泼尼龙前20 min静脉输注GSK1016790A 0.025 mg/kg;H组机械通气前30 min静脉输注HC-067047 10.0 mg/kg。机械通气4 h时,检测支气管肺泡灌洗液(BALF)中白细胞介素-1(IL-1)、肿瘤坏死因子-α(TNF-α)、总蛋白浓度,测定肺通透指数(LPI)、肺湿/干质量比(W/D),观察肺组织病理学结果。Western blot法检测肺组织TRPV4、MMP-2、MMP-9的表达水平。结果与C组比较,V组和MpG组BALF中IL-1(ng/m L:84.56±5.35 vs. 144.85±9.39、121.56±7.69)、TNF-α(ng/m L:179.65±45.73 vs. 486.18±94.79、316.93±69.71)、总蛋白(mg/m L:321.29±28.76 vs. 687.78±65.78、476.39±46.67)升高,肺组织LPI [(2.47±0.17)×10^(-3)vs.(6.19±0.29)×10^(-3)、(4.24±0.25)×10^(-3)]、W/D比值(4.42±0.19 vs. 8.83±0.61、6.32±0.41)升高,TRPV4(1.85±0.25 vs.5.81±0.92、3.87±0.65)、MMP-2 (0.44±0.06 vs. 1.16±0.23、0.85±0.11)、MMP-9(0.19±0.03 vs. 0.46±0.09、0.34±0.07)表达上调(P<0.05);与V组比较,Mp组、MpG组和H组BALF中IL-1(ng/m L:144.85±9.39 vs. 89.78±5.91、121.56±7.69、94.23±6.78)、TNF-α(ng/m L:486.18±94.79 vs. 186.42±49.37、316.93±69.71、193.71±51.41)、总蛋白(mg/m L:687.78±65.78 vs. 348.78±31.52、476.39±46.67、359.68±36.12)降低,肺组织LPI [(6.19±0.29)×10^(-3)vs.(2.85±0.14)×10^(-3)、(4.24±0.25)×10^(-3)、(2.97±0.21)×10^(-3)]、W/D比值(8.83±0.61 vs. 4.75±0.22、6.32±0.41、4.82±0.25)降低,TRPV4(5.81±0.92 vs. 2.13±0.29、3.87±0.65、2.35±0.37)、MMP-2 (1.16±0.23 vs. 0.48±0.08、0.85±0.11、0.52±0.08)、MMP-9(0.46±0.09 vs. 0.22±0.04、0.34±0.07、0.25±0.05)表达下调(P<0.05),肺组织病理损伤减轻;与Mp组比较,MpG组BALF中IL-1 (ng/m L:89.78±5.91 vs. 121.56±7.69)、TNF-α(ng/m L:186.42±49.37 vs. 316.93±69.71)、总蛋白(mg/m L:348.78±31.52 vs. 476.39±46.67)升高,肺组织LPI [(2.85±0.14)×10^(-3)vs.(4.24±0.25)×10^(-3)]、W/D比值(4.75±0.22 vs. 6.32±0.41)升高,TRPV4(2.13±0.29 vs. 3.87±0.65)、MMP-2(0.48±0.08 vs. 0.85±0.11)、MMP-9(0.22±0.04 vs. 0.34±0.07)表达上调(P<0.05)。结论甲泼尼龙可减轻大鼠VILI,与其抑制TRPV4/MMP-2/MMP-9信号通路有关。展开更多
文摘Background: Since 2021, high-risk Human Papilloma Virus (HR-HPV) testing has been the recommended screening test for cervical cancer for all settings;either used alone in a “test and treat” strategy, or with a triage test, with or without biopsy, before treatment. Cameroon has rolled out immunization against HPV 16 and 18, but studies show a higher prevalence of non-16/18 HR-HPV types. Objectives: Determine the prevalence of precancerous lesions, in women with HR-HPV infection and evaluate association of digital cervicography (DC) VIA/VILI positivity with HPV serotype, as a measure of their contribution to precancer and cancer incidence. Methodology: The study was cross-sectional, descriptive, and analytic. It took place at the Etoug-Ebe and Ekoudoum Baptist Hospitals in Yaoundé, during the period April-September 2022. We reviewed the records of women screened for cervical cancer between February 2020 and December 2021 and evaluated the prevalence of lesions on digital cervicography (DC) with VIA/VILI for women positive for HR-HPV serotypes. The data were analyzed using SPSS version 20.0 for Windows. P values Results: We identified 315 cases with a positive HR-HPV deoxyribonucleic acid (DNA) test, 224 (71.1%) had a DC VIA/VILI triage test done. Of these, 30 (13.4%) women had a positive DC VIA/VILI, with five women (2.2%) having lesions suggestive of cancer. Out of 11 cases positive for HPV 16 alone, 05 (45.5%) had a positive DC VIA/VILI test. Of the 14 cases positive for HPV 18 alone, 03 (21.4%) had a positive VIA/VILI, meanwhile only 19 (10.7%) of the 177 cases positive for non-16/18 HPV had a positive VIA/VILI test. Conclusion: A high proportion of women (13.4%) with HR HPV had a positive DC VIA/VILI, with a significant proportion (2.2%) having lesions suggestive of invasive cervical cancer HR-HPV serotype was associated with DC VIA/VILI positivity;HPV 16 had the strongest association (45.5%), followed by HPV 18 (21.4%), and non-16/18 HR-HPV (10.7%), suggesting a decreasing order of oncogenicity.
基金This work was supported by National Natural Science Foundation of China(82273141,31961160727,81973339)National Key Research and Development Program of China(2021YFC2501000)Key Laboratory of Guangdong Higher Education Institutes(2021KSYS009).
文摘Hepatocellular carcinoma(HCC)is one of the most common malignant tumors.Identification of the underlying mechanism of HCC progression and exploration of new therapeutic drugs are urgently needed.Here,a compound library consisting of 419 FDA-approved drugs was taken to screen potential anticancer drugs.A series of functional assays showed that desloratadine,an antiallergic drug,can repress proliferation in HCC cell lines,cell-derived xenograft(CDX),patient-derived organoid(PDO)and patient-derived xenograft(PDX)models.N-myristoyl transferase 1(NMT1)was identified as a target protein of desloratadine by drug affinity responsive target stability(DARTS)and surface plasmon resonance(SPR)assays.Upregulation of NMT1 expression enhanced but NMT1 knockdown suppressed tumor growth in vitro and in vivo.Metabolic labeling and mass spectrometry analyses revealed that Visinin-like protein 3(VILIP3)was a new substrate of NMT1 in protein N-myristoylation modification,and high NMT1 or VILIP3 expression was associated with advanced stages and poor survival in HCC.Mechanistically,desloratadine binds to Asn-246 in NMT1 and inhibits its enzymatic activity,disrupting the NMT1-mediated myristoylation of the VILIP3 protein and subsequent NFκB/Bcl-2 signaling.Conclusively,this study demonstrates that desloratadine may be a novel anticancer drug and that NMT1-mediated myristoylation contributes to HCC progression and is a potential biomarker and therapeutic target in HCC.
文摘目的评价甲泼尼龙对呼吸机相关性肺损伤(VILI)大鼠肺组织瞬时受体电位香草酸4 (TRPV4)/基质金属蛋白酶2/9(MMP-2/MMP-9)信号通路的影响。方法清洁级雄性SD大鼠100只,采用随机数字表法分为5组(n=20):对照组(C组)、机械通气组(V组)、甲泼尼龙组(Mp组)、甲泼尼龙+GSK1016790A组(MpG组)、HC-067047组(H组)。C组不行机械通气,自主呼吸空气4 h;V组机械通气(RR 40次/min,VT 40 m L/kg,I∶E 1∶1,PEEP 0,Fi O221%) 4 h;Mp组在机械通气前20 min静脉输注甲泼尼龙10.0 mg/kg;MpG组在给予甲泼尼龙前20 min静脉输注GSK1016790A 0.025 mg/kg;H组机械通气前30 min静脉输注HC-067047 10.0 mg/kg。机械通气4 h时,检测支气管肺泡灌洗液(BALF)中白细胞介素-1(IL-1)、肿瘤坏死因子-α(TNF-α)、总蛋白浓度,测定肺通透指数(LPI)、肺湿/干质量比(W/D),观察肺组织病理学结果。Western blot法检测肺组织TRPV4、MMP-2、MMP-9的表达水平。结果与C组比较,V组和MpG组BALF中IL-1(ng/m L:84.56±5.35 vs. 144.85±9.39、121.56±7.69)、TNF-α(ng/m L:179.65±45.73 vs. 486.18±94.79、316.93±69.71)、总蛋白(mg/m L:321.29±28.76 vs. 687.78±65.78、476.39±46.67)升高,肺组织LPI [(2.47±0.17)×10^(-3)vs.(6.19±0.29)×10^(-3)、(4.24±0.25)×10^(-3)]、W/D比值(4.42±0.19 vs. 8.83±0.61、6.32±0.41)升高,TRPV4(1.85±0.25 vs.5.81±0.92、3.87±0.65)、MMP-2 (0.44±0.06 vs. 1.16±0.23、0.85±0.11)、MMP-9(0.19±0.03 vs. 0.46±0.09、0.34±0.07)表达上调(P<0.05);与V组比较,Mp组、MpG组和H组BALF中IL-1(ng/m L:144.85±9.39 vs. 89.78±5.91、121.56±7.69、94.23±6.78)、TNF-α(ng/m L:486.18±94.79 vs. 186.42±49.37、316.93±69.71、193.71±51.41)、总蛋白(mg/m L:687.78±65.78 vs. 348.78±31.52、476.39±46.67、359.68±36.12)降低,肺组织LPI [(6.19±0.29)×10^(-3)vs.(2.85±0.14)×10^(-3)、(4.24±0.25)×10^(-3)、(2.97±0.21)×10^(-3)]、W/D比值(8.83±0.61 vs. 4.75±0.22、6.32±0.41、4.82±0.25)降低,TRPV4(5.81±0.92 vs. 2.13±0.29、3.87±0.65、2.35±0.37)、MMP-2 (1.16±0.23 vs. 0.48±0.08、0.85±0.11、0.52±0.08)、MMP-9(0.46±0.09 vs. 0.22±0.04、0.34±0.07、0.25±0.05)表达下调(P<0.05),肺组织病理损伤减轻;与Mp组比较,MpG组BALF中IL-1 (ng/m L:89.78±5.91 vs. 121.56±7.69)、TNF-α(ng/m L:186.42±49.37 vs. 316.93±69.71)、总蛋白(mg/m L:348.78±31.52 vs. 476.39±46.67)升高,肺组织LPI [(2.85±0.14)×10^(-3)vs.(4.24±0.25)×10^(-3)]、W/D比值(4.75±0.22 vs. 6.32±0.41)升高,TRPV4(2.13±0.29 vs. 3.87±0.65)、MMP-2(0.48±0.08 vs. 0.85±0.11)、MMP-9(0.22±0.04 vs. 0.34±0.07)表达上调(P<0.05)。结论甲泼尼龙可减轻大鼠VILI,与其抑制TRPV4/MMP-2/MMP-9信号通路有关。
